Hagop Kantarjian, M.D.

Please check our recent Seminar review in @thelancet.com discussing the biology of #ALL and evolution of treatment for both pediatric and adult patients
@mdanderson.bsky.social #Leukemia
www.thelancet.com/journals/lan...
#leusm

There have been major advances in #ALL therapy over the last decade. Check out our review just published in Cancer Journal
discussing these advances & revolution in adult ALL therapy.
@mdanderson.bsky.social #Leukemia
doi.org/10.1002/cncr...
#leusm

SQ blinatumomab is highly effective in R-R ALL with CR/CRh rate of 77%, MRD-negativity rate of 91%, and 12-month OS rate of 63-70%.

The 250 µg/500 µg dose was selected as the recommended phase 2 dose.
@mdanderson.bsky.social
#Leukemia
doi.org/10.1016/s235...
#leusm

Management of chronic myeloid leukemia in 2025 Chronic myeloid leukemia (CML) management has evolved significantly with BCR::ABL1 tyrosine kinase inhibitors (TKIs), which has reduced annual mortality to 1% and will increase prevalence to more tha...

A comprehensive review on the management of #CML in 2025 written by an international group of CML experts.
@mdanderson.bsky.social #Leukemia
doi.org/10.1002/cncr...
#leusm

WBC >70K (but not IKZF1plus) increases risk of relapse with blina+ponatinib in Ph+ ALL, particularly extramedullary/CNS. Pts with high WBC should be considered for systemic MTX/Ara-C and/or CAR T-cell consolidation
@mdanderson.bsky.social
jhoonline.biomedcentral.com/articles/10....
#leusm #ALL

New in Leukemia Journal: Outcomes in intensively treated KMT2Ar #AML have improved over time. But low-intensity therapies still show poor results — highlighting the urgent need to explore menin inhibitors
www.nature.com/articles/s41...
#leusm
@mdanderson.bsky.social

Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research Chronic myeloid leukemia is typically effectively managed with BCR::ABL1 tyrosine kinase inhibitors (TKIs) but treatment resistance and intolerance are persistent challenges. Olverembatinib is a thir...

Historical development, current status, and future research of olverembatinib, a new third-generation BCR::ABL1 TKI with significant activity and favorable safety profile:
@mdanderson.bsky.social #Leukemia
dx.doi.org/10.1002/cncr...
#leusm #CML

First report of the Ph 2 trial of the CLIA regimen in pts w/ R/R #AML: CR/CRi of 49% & median OS of 12 months in pts who received it as 1st salvage rx. Data provides tolerable & effective backbone upon which to build combination strategies @mdanderson.bsky.social
doi.org/10.1002/cncr...

Ph 1b/2 trial of Aza-Ven-Magro in newly-diagnosed high-risk and R/R #AML: Clinical data & correlative analysis @theaacr.bsky.social
doi.org/10.1158/1078...
Unfortunately, the neg Ph3 ENHANCE trials terminates research w/ Magrolimab and likely anti-CD47 Rx in AML for now
@mdanderson.bsky.social

Check out our comprehensive review on #AML from an @mdanderson.bsky.social perspective, " Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges" published in @acsjournalcancer.bsky.social

acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
#leusm

Review of Chronic Myeloid Leukemia This Review summarizes the epidemiology, diagnosis, and management of chronic myeloid leukemia.

Check out our comprehensive review of Chronic Myeloid Leukemia published in @jama.com
Listen to our interview available through the link:
jamanetwork.com/journals/jam...
@mdanderson.bsky.social #Leukemia
@ EJabbour @drhkantarjian.bsky.social
#leusm #CML

In this large retrospective study of FLT3-mutated AML, we confirm the important role of FLT3 inhibitors in intensively treated pts and demonstrate promising outcomes w/ low-intensity triplets in older/unfit pts
@mdanderson.bsky.social #Leukemia
@americancancersoc.bsky.social doi.org/10.1002/cncr...

Expert recommendations on using MRD in #ALL now out in @bloodadvances.bsky.social. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT
@mdanderson.bsky.social #Leukemia
doi.org/10.1182/bloo...
#leusm

Oral formulation of arsenic trioxide has similar pharmacokinetics to the intravenous drug, allowing potential future all oral therapy in acute promyelocytic leukemia
@mdanderson.bsky.social #Leukemia
doi.org/10.1182/bloo...
@ash.hematology.org
#leusm

Updated results of our frontline trial of FLAG-IDA+VEN, showing CRc in 95% of newly diagnosed #AML. Responses were seen across all ELN22 risk groups, w/ 90% MRD neg. In RR AML, 79% first salvage & TP53wt attained CRc.
@mdanderson.bsky.social
rdcu.be/ebcvm
#leusm

Treatment-free remission in non-transplanted Ph+ #ALL pts is feasible in carefully selected pts. Those in CR1 (n=6) who maintained CMR for >48 mos did not relapse following TKI discontinuation.
@mdanderson.bsky.social
doi.org/10.1002/cncr...
@nitinjainmd.bsky.social @niranjankhaire.bsky.social

Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT.
@mdanderson.bsky.social #Leukemia
@ash.hematology.org
ashpublications.org/bloodadvance...

Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies Outcomes of patients with secondary-type acute myeloid leukemia.

Genomic secondary #AML: Heterogenous group w/ outcomes variable based on presence of secondary type mutations or cytogenetics
@mdanderson.bsky.social #Leukemia Kantarjian, DiNardo, Loghavi, Senapati @jayastumd.bsky.social American Journal of Hematology onlinelibrary.wiley.com/doi/10.1002/...
#leusm

Treated secondary #AML is an adverse subtype of AML that warrants an independent prognostic designation
@mdanderson.bsky.social #Leukemia
Kantarjian, Kadia, Senapati, @jayastumd.bsky.social
American Journal of Hematology
onlinelibrary.wiley.com/doi/10.1002/...
#leusm